Bibliografia UJ CM



Zapytanie: DOUGHERTY FRANK C
Liczba odnalezionych rekordów: 5



Przejście do opcji zmiany formatu | Wyświetl/ukryj etykiety | Wersja do druku | | | Nowe wyszukiwanie
1/5
Johannes Mann, Francesco Locatelli, Wladyslaw Sulowicz, Allen Nissenson, Jose Portoles, Nathan Levin, Michael Del Aguila, Frank C. Dougherty.
C.E.R.A. provides stable haemoglobin (Hb) levels in CKD patients on dialysis with and without coronary artery disease (CAD) or diabetes mellitus (DM) when administered once monthly.
Nephrology, Dialysis, Transplantation
2007 : Vol. 22 suppl. 6, s. vi411, abstr. SuO002
XLIV Congress of the Europeean Renal Association, European Dialysis and Transplant Association (ERA-EDTA), Barcelona. Spain, June 21-24, 2007.
SZZ
SIF
2/5
Marian Klinger, Manual Arias, Vassilis Vargemezis, Anatole Besarab, Wladyslaw Sulowicz, Trevor Gerntholtz, Kazimierz Ciechanowski, Frank C. Dougherty, Ulrich Beyer, the AMICUS Study Investigators.
Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis : a randomized trial.
American Journal of Kidney Diseases
2007 : Vol. 50, nr 6, s. 989-1000, il., bibliogr.
p-ISSN: 0272-6386
AZ
ORG
AIF
IF: 3.981
Adres url:
3/5
Wladyslaw Sulowicz, Francesco Locatelli, Jozef Balla, Batond Csiky, Casba Rikker, Jean-Claude Aldigier, Frank C. Dougherty.
Subcutaneous (SC) C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis.
Nephrology, Dialysis, Transplantation
2006 : Vol. 21 suppl. 4, s. iv156, abstr. SP424
XLIII Congress of the European Renal Association, European Dialysis and Transplant Association (ERA-EDTA), Glasgow, United Kingdom, July 15-18, 2006.
SZZ
SIF
4/5
Anatole Beserab, Robert Provenzano, Iain C. Macdougall, David H. Ellison, A. Peter Maxwell, Wladyslaw Sulowicz, Frank C. Dougherty.
Dose-dependent erythropoietic responses to subcutaneous (SC) CERA (Continuous Erythropoietin Receptor Activator) in a multi-dose study of patients with Chronic Kidney Disease (CKD) not on dialysis.
W: The American Society of Nephrology (ASN) 38th Annual Meeting, November 8-13, 2005
il. : bibliogr. 3 poz.
SZZ
AWZ
5/5
Robert Provenzano, Anatole Beserab, Iain C. Macdougall, David H. Ellison, A. Peter Maxwell, Wladyslaw Sulowicz, Frank C. Dougherty.
Subcutaneous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin levels with administration intervals up to 3 weeks in chronic kidney disease patients not on dialysis.
W: The American Society of Nephrology (ASN) 38th Annual Meeting, November 8-13, 2005
il. : bibliogr. 3 poz.
SZZ
AWZ
  Wyświetl ponownie stosując format:
Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ